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Abstract
Background and purpose
Anemia is associated with worse outcome in stroke, but the impact of anemia with intrave-
nous thrombolysis or endovascular therapy has hardly been delineated. The aim of this
study was to analyze the role of anemia on infarct evolution and outcome after acute stroke
treatment.
Methods
1158 patients from Bern and 321 from Los Angeles were included. Baseline data and 3
months outcome assessed with the modified Rankin Scale were recorded prospectively.
Baseline DWI lesion volumes were measured in 345 patients and both baseline and final
infarct volumes in 180 patients using CT or MRI. Multivariable and linear regression analysis
were used to determine predictors of outcome and infarct growth.
Results
712 patients underwent endovascular treatment and 446 intravenous thrombolysis. Lower
hemoglobin at baseline, at 24h, and nadir until day 5 predicted poor outcome (OR 1.150–
1.279) and higher mortality (OR 1.131–1.237) independently of treatment. Decrease of
hemoglobin after hospital arrival, mainly induced by hemodilution, predicted poor outcome
and had a linear association with final infarct volumes and the amount and velocity of infarct
growth. Infarcts of patients with newly observed anemia were twice as large as infarcts with
normal hemoglobin levels.
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Conclusion
Anemia at hospital admission and any hemoglobin decrease during acute stroke treatment
affect outcome negatively, probably by enlarging and accelerating infarct growth. Our
results indicate that hemodilution has an adverse effect on penumbral evolution. Whether
hemoglobin decrease in acute stroke could be avoided and whether this would improve out-
come would need to be studied prospectively.
Introduction
Anemia is a frequently observed pre-existing condition in ischemic stroke patients. A recent
meta-analysis of conservatively treated patients indicated a prevalence of 21.9%.[1] According
to previous studies, anemia has a negative effect on outcome in conservatively treated patients.
[2–6] In addition, two recent meta-analyses including more than 19,000 patients confirmed an
increased mortality in such patients with anemia (OR 1.39 respectively 1.97). [1,7] Whether
anemia has also an impact in stroke patients treated with intravenous thrombolysis (IVT) or
endovascular therapy (EVT), which aim to rescue the penumbral tissue, has hardly been stud-
ied. There is only one study on anemia and patients treated with IVT. [8] Anemia was associ-
ated with worse outcome, but the impact of anemia in EVT is unknown.
It is a matter of debate, whether the negative association of anemia and stroke outcome is
simply based on comorbidities that cause the anemia, or whether decreased oxygen-carrying
capacity with anemia accelerates the decay of the penumbra because of reduced oxygen supply
to the jeopardized tissue. Two studies described an association of anemia and further hemoglo-
bin decrease with infarct growth. [9,10] They would support the latter mechanism. However,
the two studies did not take reperfusion success into account and did not restrict their analysis
to patients without anemia at hospital admission. Therefore, a confounding effect of reperfu-
sion and comorbidities cannot be ruled out.
The aim of this study was to analyze the impact of anemia at hospital admission and hemo-
globin decrease during treatment on stroke outcome and infarct growth in a large cohort of
patients treated with EVT and IVT.
Patients and methods
Patients and treatment
The present study includes patients of the Bernese stroke registry, a prospectively collected
data base that had been used also for other studies. [11–15] Patients were included in this anal-
ysis if: 1) they underwent IVT, EVT or bridging IVT and EVT between January 2011 and June
2015 and 2) at least baseline laboratory parameters were available.
The treating neurologist and neuroradiologist decided whether to perform IVT, EVT or
bridging therapy on a case by case basis considering the radiological findings and patient’s
baseline characteristics. They comprised age, gender, National Institutes of Health Stroke Scale
(NIHSS) score, location of vessel occlusion, time from symptom onset to treatment, atrial
fibrillation, hypertension, diabetes, smoking, and hypercholesterolemia. Decision for perform-
ing MR or CT at admission was performed on an individual bases. Usually MR was performed
in all patients expect for patients with contraindications for MR and patients suffering from
vomiting. Reperfusion after EVT was graded by TICI scores. A CT or MRI scan was obtained
24h to 72h after treatment or in any case of clinical deterioration. Symptomatic intracranial
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hemorrhage (sICH) was graded according to the definition of the PROACT II Study. [16]
Clinical outcome was assessed 3 months after the stroke using the modified Rankin Scale
(mRS).
Consecutive patients treated at the David Geffen School of Medicine in Los Angeles with
IVT or EVT between April 2012 and October 2016 and who had perfusion CT or MR at base-
line served as comparison for the amount of hemoglobin decrease after hospital arrival. The
data was obtained from a prospective collected data base. Missing parameters were obtained
retrospectively if available. The study was performed with approval of the local ethics commit-
tees of Bern without the need for written informed consent. All data were anonymized before
processing.
Laboratory parameters
Blood was collected in plastic syringes containing 1.6 ml EDTA per ml of blood (Monovette1,
Sarstedt, Nu¨mbrecht, Germany). Samples were analyzed using an automated hematology ana-
lyzer (Coulter Counter LH750, Beckman-Coulter Inc., Nyon, Switzerland). Pre-treatment lab-
oratory results of hemoglobin, hematocrit, and erythrocytes and if available, 24h follow up
results and nadir until day 5 were collected retrospectively. Anemia was defined according to
the World Health Organization criteria as hemoglobin below 12 g/dL in women and below 13
g/dL in men.
Blood pressure and infusion therapy
In patients in whom segmentation of the final infarct volume was performed, the follow-
ing additional parameters were collected retrospectively: systolic blood pressure (BP)
<120mmHg, systolic BP <110mmHg or BP drop of > 20mmHg within the first 24h and
48h, systolic BP nadir until 48h, infusion volume within 24h and 48h, and use of vasoac-
tive medication.
Imaging methods and analysis
MRI was performed using a 1.5T or 3T MR imaging system (Siemens Magnetom Avanto/
Aera/Verio, Siemens Medical Solution, Erlangen, Germany). The MRI protocol included
whole brain diffusion weighted imaging (DWI) (b = 1000t, 24 slices, thickness 5 mm, TR
3200ms, TE 87ms, number of averages 2, matrix 256×256) yielding isotropic b0 and b1000.
ADC maps were calculated according to the exponential relation S(b) = S(0) exp(–b • ADC),
where S(b) is the signal intensity using diffusion weighting with the value b, and S(0) is the sig-
nal intensity with b = 0. Segmentation of the DWI lesion in pre-treatment imaging was per-
formed with the OLEA Sphere Software1 (OLEA Medical, La Ciotat, France) by S.B. in all
patients who underwent MRI before endovascular treatment. Segmentation of the final infarct
was performed with 3D slicer version 4.5.0–1 (manual slice-by-slice delineation with “draw”
and “paint” tools by M.B., S.F., controlled by A.H.) in all patients with pre-treatment MRI,
who received follow-up imaging by MRI (FLAIR or T2, slice thickness 5mm) or CT (slice
thickness 3mm, Siemens Definition Edge, Siemens Healthcare, Erlangen, Germany) 14 days or
later after stroke. Baseline and follow-up images were compared before segmentation to
exclude the inclusion of infarcts from previous stroke.
Statistical analysis
SPSS 21 (SPSS Inc., Chicago, Illinois, USA) served for statistical analysis. Bivariable
analysis of categorical variables was performed with χ2 and Fisher’s exact test as
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appropriate and continuous variables with Mann-Whitney test. Because baseline and
final infarct volumes and time from symptom onset to treatment were not normally dis-
tributed, the natural logarithm-transformed variables were used. Infarct growth velocity
was defined as infarct growth velocity ¼ final infarct volume  baseline infarct volumetime from MRI to reperfusion .
Outcome was dichotomized into favorable (mRS 0–2) or poor clinical outcome (mRS 3–6).
Forward stepwise logistic regression analysis including all variables with p<0.2 in bivariate
analysis (all baseline characteristics and hemoglobin parameters) was used to determine the
predictors of outcome and survival. Linear regression analysis was used to determine the pre-
dictors of baseline infarct volume, final infarct volume, infarct growth, and velocity of infarct
growth by inclusion of the same variables and, if appropriate, reperfusion success, time from
MRI to reperfusion, systolic BP <120mmHg, <110mmHg or BP drop of> 20mmHg within
the first 24h and 48h, systolic BP nadir until 48h, infusion volume within 24h and 48h, and use
of vasoactive medication. Subgroup analyses were performed for infarct growth and velocity of
infarct growth in patients without anemia at baseline. Each laboratory parameter (hemoglobin
baseline, 24h, nadir until day 5, hemoglobin decrease) entered separately into the final models
to test their significance.
Linear regression analysis was used to determine the predictors of hemoglobin decrease by
inclusion of the variables systolic BP nadir, amount of infusion until 24h, time from MRI to
reperfusion, and baseline characteristics.
A p-value < 0.05 was considered significant.
The blood loss that equates to hemoglobin decrease after hospital arrival was estimated by
the formula V ¼ EBV  ln hemoglobin baselinehemoglobin nadir
 
, where V indicates the volume and EBV the
patient’s estimated blood volume. [17] EBV was estimated by multiplying the gender depen-
dent mean body weight of the Swiss population[18] by 65 ml/kg for women and 75 ml/kg for
men.
Results
Baseline characteristics and laboratory parameters
Baseline characteristics of the 1158 included patients are listed in Table 1. Pre-treatment and
follow up laboratory parameters are listed in Table 2. Hemoglobin at admission was available
for all 1158 patients, hemoglobin at 24h for 939 patients, and hemoglobin nadir until day 5 for
960 patients. Anemia at hospital admission was observed in 191 (26.8%) of the patients treated
with EVT and 92 (20.6%) of the patients treated with IVT. Until day 5, anemia occurred or
was unmasked because of fluid replacement in 491/600 (81.8%) of the patients treated with
EVT and 181/360 (50.3%) of the patients treated with IVT. Newly observed anemia between
hospital arrival and day 5 was noted in 332/600 (46.6%) of the patients treated with EVT and
106/360 (29.4%) of the patients treated with IVT.
Predictors of 3 months’ outcome and survival
The predictors of outcome, survival and infarct volumes are listed in Table 3. In multivariable
regression analysis hemoglobin at baseline, hemoglobin at 24h, hemoglobin nadir until day 5
and hemoglobin decrease until day 5 were independent predictors of outcome. Lower hemo-
globin levels or larger decrease were associated with worse outcome. The results were indepen-
dent from the treatment modality.
Hemoglobin at baseline, hemoglobin at 24h, and hemoglobin nadir until day 5 were inde-
pendent predictors of survival.
Anemia, infarct growth and stroke outcome
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The distribution of 3 months’ outcome as measured by modified Rankin Scale score in
dependence on baseline anemia and newly observed anemia until day 5 is illustrated in Fig 1.
Among 8 patients with newly observed anemia until day 5, one patient achieved a less favor-
able outcome in our cohort (Number Needed to Harm 7.4).
Predictors of infarct size and growth
Segmentation of MRI was performed in 345 patients treated with EVT to assess baseline infarct
volume. Both baseline and final infarct volumes were obtained of 180 patients. Successful
reperfusion (TICI score 2b-3) was achieved in 135 (75%) of them. The infarct volumes and
velocity of infarct growth in dependence on newly observed anemia until day 5 and reperfu-
sion success are listed in Table 4. The mean infarct volume at baseline was 27 cm3 (SD 36) and
the final infarct volume 41 cm3 (SD 66). Hemoglobin at baseline was an independent predictor
of the baseline infarct volume in linear regression analysis (Table 3 and Fig 2). The mean base-
line infarct volume in patients without anemia at hospital admission was 25 cm3 (SD 34) and
33 cm3 (SD 42) in those with anemia at hospital admission. Hemoglobin decrease until 24h
was an independent predictor of infarct growth and hemoglobin decrease until day 5 an inde-
pendent predictor of the final infarct volume and infarct growth (S1 Fig). Hemoglobin
decrease until 24h and until day 5 were also independent predictors of the velocity of infarct
Table 1. Baseline characteristics and outcome of 1158 treated patients.
EVT
(n = 712)
IVT
(n = 446)
Age, years (SD) 71 (13.9) 72.2 (13.6)
Women 352 (49.4%) 172 (38.6%)
Vascular risk factors
- Hypertension 518/710 (73%) 330/444 (74.3%)
- Diabetes mellitus 132/708 (18.6%) 82/444 (18.5%)
- Atrial fibrillation 297/610 (48.7%) 149/394 (37.8%)
- Current smoking 150/578 (26%) 66/386 (17.1%)
- Hypercholesterolemia 400/697 (57.4%) 268/443 (60.5%)
Baseline NIHSS score, median (range) 15 (0–36) 7 (0–36)
Vessel occlusion location
- No occlusion 0 7.6)
- Internal carotid artery 220 (30.9) 5.8)
- Middle cerebral artery 407 (57.2) 0.7)
- Anterior cerebral artery 4 (0.6) 2.7)
- Posterior cerebral artery 14 (2) 6.3)
- Vertebrobasilar system 67 (9.4) 31 (7)
Treatment
- EVT without prior IVT 414/712 (58.1) -
- Bridging therapy (IVT + EVT) 298/712 (41.9) -
Minutes from symptom onset to treatment, median (range) 265 (70–1663) 180 (60–1680)
Outcome
- mRS 0–2 253/642 (39.4) 249/398 (62.6)
- Survival 467/642 (72.7) 333/398 (83.7)
Complications
- Symptomatic ICH 32/697 (4.6) 16/428 (3.7)
EVT = endovascular treatment, IVT = intravenous thrombolysis
https://doi.org/10.1371/journal.pone.0203535.t001
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growth. In subgroup analysis after exclusion of patients with TICI scores 0 or 1, in whom the
infarct growth continues after failed recanalization with the endovascular procedure, this
result remained robust.
The hemoglobin decrease until day 5 proved as predictor of the amount and velocity of
infarct growth velocity also in the subgroup of patients with normal hemoglobin at hospital
admission. Newly observed anemia until day 5 was an independent predictor of the final
infarct volume, infarct growth and infarct growth velocity.
Predictors of hemoglobin decrease
There was an association between hemoglobin decrease until day 5 and the systolic BP nadir
(p = 0.035) and the amount of infusion (p = 0.011) in bivariable analysis. In linear regression
analysis, the time from MRI to reperfusion (p = 0.001, regression coefficient -0.006, T =
-3.512) and the systolic BP nadir (p = 0.005, regression coefficient 0.020, T = 2.850) were pre-
dictors of hemoglobin decrease until day 5. The mean hemoglobin decrease of 2.2 g/dl in
patients treated with EVT equates to an estimated amount of blood loss of 890ml, and the
decrease of 1.3 g/dl in patients treated with IVT to an estimated amount of 490ml.
Comparison group of patients treated at the David Geffen School of
Medicine in Los Angeles
In patients treated at the David Geffen School of Medicine, Los Angeles, the mean hemoglobin
decrease until day 5 was -1.8g/dl (SD 1.3) in 160 patients treated with IVT and -2.3g/dl (SD
1.4) in 161 patients treated with EVT.
Table 2. Laboratory baseline and follow up parameters (n = 1158 for hemoglobin at admission, n = 939 for hemo-
globin at 24h and n = 960 for hemoglobin nadir until day 5).
EVT
(n = 712)
IVT
(n = 446)
Patients treated at University Hospital Bern, Switzerland
Hemoglobin baseline, g/dl mean (SD) 13.2 (1.9) 13.7 (1.6)
Hemoglobin 24h, g/dl mean (SD) 11.4 (1.7) 12.8 (1.6)
Hemoglobin nadir until day 5, g/dl mean (SD) 11.1 (1.7) 12.4 (1.7)
Hemoglobin decrease until day 5, g/dl mean (SD) -2.2 (1.4) -1.3 (1.1)
Hematocrit baseline, l/l mean (SD) 0.45 (1.49) 0.41 (0.05)
Hematocrit 24h, l/l mean (SD) 0.34 (0.05) 0.38 (0.05)
Hematocrit nadir until day 5, l/l mean (SD) 0.33 (0.05) 0.37 (0.05)
Erythrocytes at baseline, T/l mean (SD) 4.30 (0.58) 4.43 (0.5)
Erythrocytes 24h, T/l mean (SD) 3.74 (0.56) 4.15 (0.52)
Erythrocytes nadir until day 5, T/l mean (SD) 3.62 (0.59) 4.03 (0.56)
Anemia
Anemia at hospital admission 191/712 (26.8) 92/446 (20.6)
Anemia at 24h 444/591 (75.1) 142/348 (40.8)
Anemia until day 5 491/600 (81.8) 181/360 (50.3)
Newly observed anemia until 24h 290/591 (49.1) 80/348 (23)
Newly observed anemia until day 5 332/600 (46.6) 106/360 (29.4)
Patients treated at David Geffen School Los Angeles, USA
Hemoglobin decrease until day 5, g/dl mean (SD) -2.3 (1.4) -1.8 (1.3)
EVT = endovascular treatment, IVT = intravenous thrombolysis
https://doi.org/10.1371/journal.pone.0203535.t002
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Discussion
The main finding of our study is that anemia at hospital admission and any decrease of hemo-
globin are associated with worse outcome and higher mortality in patients treated with IVT or
Table 3. Predictors of outcome and survival in multivariable regression analysis and of infarct volumes and
infarct growth in linear regression analysis. For each laboratory parameter, a separate analysis was performed and
the results shown for other non-laboratory parameters are based on the model with inclusion of the first listed labora-
tory parameter. Hemoglobin at admission was available for 1158 patients, hemoglobin at 24h for 939 patients, and
hemoglobin nadir until day 5 for 960 patients.
Predicting factor P OR 95% CI
mRS 0–2
Age < 0.001 0.945 0.932–0.958
Diabetes mellitus < 0.001 0.415 0.271–0.635
NIHSS score baseline < 0.001 0.865 0.843–0.887
Time symptom onset to treatment < 0.001 0.451 0.317–0.642
sICH < 0.001 0.034 0.007–0.164
Hemoglobin baseline 0.001 1.177 1.069–1.295
Hemoglobin 24h 0.013 1.150 1.030–1.284
Hemoglobin nadir day 5 < 0.001 1.279 1.155–1.416
Hemoglobin decrease until day 5 0.010 1.193 1.043–1.365
Erythrocytes 24h 0.009 1.559 1.119–2.172
Erythrocytes nadir day 5 <0.001 2.265 1.668–3.076
Survival
Age < 0.001 0.944 0.929–0.960
Diabetes mellitus 0.01 0.490 0.324–0.741
NIHSS score baseline < 0.001 0.903 0.883–0.924
sICH < 0.001 0.080 0.037–0.171
Hemoglobin baseline < 0.001 1.194 1.081–1.320
Hemoglobin 24h 0.032 1.131 1.010–1.266
Hemoglobin nadir day 5 < 0.001 1.237 1.110–1.379
Erythrocytes 24h 0.002 1.633 1.189–2.244
Erythrocytes nadir day 5 <0.001 2.356 1.758–3.158
Predicting factor P Regression coefficient T
Baseline infarct volume (based on 345 patients)
Age 0.001 -0.017 -3.241
Male gender 0.036 -0.323 -2.109
Hemoglobin baseline 0.014 -0.109 -2.475
Final infarct volume (based on 180 patients)
Reperfusion success 0.006 -0.321 -2.788
Systolic BP nadir 0.014 0.022 2.491
Hemoglobin decrease until day 5 0.002 -0.285 -3.146
Newly overserved anemia until day 5 0.023 0.605 2.300
Infarct growth (based on 180 patients)
Reperfusion success < 0.001 -16.299 -5.267
Hemoglobin decrease until day 5 0.003 -7.596 -3.012
Newly overserved anemia until day 5 0.022 16.964 2.308
Velocity infarct growth (based on 180 patients)
Reperfusion success < 0.001 -5.026 -3.979
Hemoglobin decrease until day 5 0.001 -3.514 -3.414
Newly observed anemia until day 5 0.016 7.368 2.442
https://doi.org/10.1371/journal.pone.0203535.t003
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Fig 1. Distribution of 3 months outcome (as measured by modified Rankin Scale score) in dependence on anemia at hospital admission (a)
and newly observed anemia until day 5 (b).
https://doi.org/10.1371/journal.pone.0203535.g001
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EVT. This finding pertains not only to anemia at hospital admission but also to any hemoglo-
bin decrease thereafter. There was a linear relationship between hemoglobin decrease and
larger final infarct volume and greater and faster infarct growth. The reason of the relationship
of hemoglobin and outcome is unknown, but a causal relationship between lower hemoglobin
and faster infarct growth is conceivable. Anemia entails a decrease of oxygen-carrying capacity
of blood, however confounding effects like overused fluid replacement during the acute recan-
alization and reperfusion therapy or thereafter may contribute partly to this association. Exces-
sive hemodilution might impact negatively on the penumbra and optimal fluid replacement in
acute stroke would need to be addressed in further studies.
Several trials found a negative impact of anemia at hospital admission on outcome and sur-
vival in conservatively treated ischemic stroke patients. [1–7, 19] The impact of anemia in
acute stroke treatment with IVT or EVT has been addressed in only one study of 217 patients
Table 4. Association between newly observed anemia and extent of infarction in 180 patients treated with EVT.
Final infarct volume
cm3, mean (SD)
Infarct growth
cm3, mean (SD)
Velocity infarct growth
cm3/h, mean (SD)
without anemia with anemia without anemia with anemia without anemia with anemia
New anemia until day 5 26 (43) 53 (79) 5 (36) 24 (57) 0.3 (12) 9 (24)
- Reperfusion TICI 0-2a 46 (69) 101 (113) 17 (67) 59 (82) 2.5 (21) 21.5 (36)
- Reperfusion TICI 2b-3 21 (32) 34 (48) 1 (21) 10 (34) -0.2 (9) 3.2 (13)
https://doi.org/10.1371/journal.pone.0203535.t004
Fig 2. Influence of baseline anemia and newly observed anemia on mean infarct sizes and infarct growth.
https://doi.org/10.1371/journal.pone.0203535.g002
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treated with IVT, which found a negative impact of anemia on outcome and survival. [8] In
our cohort of 1158 patients, anemia at hospital admission and lower hemoglobin at any time
during the first 5 days after stroke turned out as a predictor of worse outcome and higher mor-
tality, independently from the treatment modality. In addition, a larger hemoglobin decrease
after hospital arrival was associated with worse outcome. The potential effect size, expressed as
number needed to harm for suffering unfavorable outcome due to newly observed anemia
would be 7.4. However, this effect size has to be interpreted with caution because our data are
not based on a randomized trial.
The reason for the negative effect of anemia on outcome is unknown. Two studies describ-
ing an association of anemia with infarct growth assumed that decreased oxygen-carrying
capacity with anemia might exert a negative effect on penumbra evolution. [9,10] Our study
confirms their assumption and provides additional information on the relationships of hemo-
globin, reperfusion and infarct growth. In our study, there was not only a linear relationship
between lower hemoglobin at hospital arrival and larger baseline infarct volumes, but also a
linear relationship between hemoglobin decrease after hospital arrival and greater and faster
infarct growth (S1 Fig). Hemoglobin decrease after hospital arrival turned out as the only pre-
dictor of infarct growth in addition to reperfusion failure. A similar effect was observed even
in patients in whom hemoglobin did not fall to the level of anemia definition. This indicates
that even small changes of hemoglobin concentration might jeopardize the optimal oxygen
supply to the penumbra. The hemoglobin decrease after hospital admission resulted likely
from hemodilution, because there was a linear association between hemoglobin decrease and
amount of infusion therapy and because stroke therapy does not result in significant blood
loss. The hemoglobin decrease of patients treated at the University Hospital of Bern and
patients treated at the David Geffen School in Los Angeles were similar which rules out a cen-
ter specific overuse of infusion therapy.
Our findings raise the question whether we need to rethink current infusion therapy for
stroke patients. Does infusion therapy account for worse outcome or do confounding factors
explain the accelerated infarct growth with decreasing hemoglobin? First, low BP was associ-
ated with hemoglobin decrease in our cohort and may have contributed to infarct growth by
itself. Second, longer time from CT or MRI to reperfusion turned out as predictor of hemoglo-
bin decrease, which may stand for longer infusion times and amounts because of more compli-
cated and time-consuming endovascular procedures. Third, patients with larger infarcts are
usually more severely affected, less likely able to swallow and more likely to receive intravenous
fluid replacement. Although part of the infarct growth may be explained by these three factors,
hemoglobin decrease turned out as a predictor of infarct growth independently from blood
pressure, time to successful or failed reperfusion and infarct severity. In addition, animal stud-
ies showing larger infarcts after hemodilution support a causal relationship of hemodilution
with infarct growth. [20–22] A model based on in vitro data predicts a continuous decline of
oxygen delivery in the penumbra already below hemoglobin levels of 10g/dl. [23] Assuming
no confounding factors and based on the regression coefficient for infarct growth, infusion of
1000 ml NaCl 0.9% might result in infarct growth up to 3.1ml or 7% of the mean final infarct
volume. [24–26] That hemodilution should have a negative impact on infarct size might be
somehow unexpected, because hemodilution was believed to improve outcome by enhancing
blood viscosity in earlier days and only randomized trials disproved this concept. [27] Accord-
ing to the formula Q × Hb × SaO2 × 1.39 (where Q indicates blood flow and SaO2 arterial oxy-
gen saturation), that describes oxygen delivery to the brain, any decrease of hemoglobin may
affect oxygen delivery when it is not compensated by an increased blood flow. [28] In healthy
volunteers, raised cardiac output and NO induced vasodilatation can increase cerebral blood
flow and keep oxygen delivery stable down to hemoglobin levels of 5–6 g/dl. [29,30] However,
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in the ischemic penumbra all compensatory mechanisms are exhausted and already at their
limits. [31,32] To summarize, a negative impact of even a small hemoglobin decrease induced
by hemodilution on infarct growth in acute stroke is conceivable. It needs a closer look and
further studies should investigate, whether and how it should and could be avoided.
The most important limitation of our study is its retrospective character. Therefore, we can-
not exclude confounding effects that are at least partly responsible for the association of hemo-
globin decrease with infarct growth. A further limitation is the accuracy of the determination
of the final infarct volume. It may have been influenced by the techniques of follow up imaging
(CT and MRI).
Supporting information
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S1 Fig. Adjusted predicted final infarct volumes in dependence on hemoglobin decrease
until day 5, calculated by linear regression analysis by inclusion of factors reperfusion suc-
cess and systolic blood pressure nadir.
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